Michael Barbella, Managing Editor03.20.24
BioStem Technologies Inc. has appointed life science sales leader Shawn McCarrey as chief commercial officer.
“We expect 2024 to be a transformative year for BioStem, and investing in our leadership is an important step towards strengthening our current presence in the wound management space, in addition to breaking into new markets,” BioStem Technologies CEO Jason Matuszewski said. “I am thrilled to announce Mr. McCarrey's arrival at BioStem and eagerly anticipate the valuable insights and dynamic strategies he will contribute. His extensive background, marked by significant achievements in transforming care standards in diverse fields such as regenerative medicine, wound care, and podiatry, is highly impressive. Mr. McCarrey's history of success is a testament to his capabilities. We are confident that his involvement will greatly benefit BioStem's commercial endeavors, as well as our customers and investors.”
Before joining BioStem Technologies, McCarrey was chief commercial officer at BLUEWAVE, successfully commercializing its proprietary system in Orthotics & Prosthetics (O&P), Wound Care, and Podiatry markets. Prior to that, he was vice president of Sales at Glytec, and worked as senior vice president of Sales in the regenerative medicine sector at AxoGen. During his Axogen tenure, McCarrey was instrumental in boosting the company's annual growth rate from 39% to 60%. He also brings valuable leadership experience from his time at Bayer, where he significantly expanded the company's install base by 910% and grew its sales force by 250%. At Possis Medical, McCarrey was pivotal in launching 16 new products over a decade, contributing to a substantial 1,158% increase in the company's sales.
“BioStem has reached an important inflection point and has a unique opportunity to realize a number of market opportunities in the coming year," McCarrey stated. "I am very pleased to join BioStem to champion the company’s team as it capitalizes on these opportunities.”
BioStem Technologies is focused on harnessing the natural properties of perinatal tissue in developing, manufacturing, and commercializing allografts for regenerative therapies. The company manufactures products leveraging its proprietary BioREtain processing method. BioREtain has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (AATB). These systems and procedures are established per current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). Its portfolio of brands includes AmnioWrap2, VENDAJE, VENDAJE AC, and VENDAJE OPTIC. Each BioStem Technologies placental allograft is processed at the company's U.S. Food and Drug Administration-registered and AATB-accredited site in Pompano Beach, Fla.
“We expect 2024 to be a transformative year for BioStem, and investing in our leadership is an important step towards strengthening our current presence in the wound management space, in addition to breaking into new markets,” BioStem Technologies CEO Jason Matuszewski said. “I am thrilled to announce Mr. McCarrey's arrival at BioStem and eagerly anticipate the valuable insights and dynamic strategies he will contribute. His extensive background, marked by significant achievements in transforming care standards in diverse fields such as regenerative medicine, wound care, and podiatry, is highly impressive. Mr. McCarrey's history of success is a testament to his capabilities. We are confident that his involvement will greatly benefit BioStem's commercial endeavors, as well as our customers and investors.”
Before joining BioStem Technologies, McCarrey was chief commercial officer at BLUEWAVE, successfully commercializing its proprietary system in Orthotics & Prosthetics (O&P), Wound Care, and Podiatry markets. Prior to that, he was vice president of Sales at Glytec, and worked as senior vice president of Sales in the regenerative medicine sector at AxoGen. During his Axogen tenure, McCarrey was instrumental in boosting the company's annual growth rate from 39% to 60%. He also brings valuable leadership experience from his time at Bayer, where he significantly expanded the company's install base by 910% and grew its sales force by 250%. At Possis Medical, McCarrey was pivotal in launching 16 new products over a decade, contributing to a substantial 1,158% increase in the company's sales.
“BioStem has reached an important inflection point and has a unique opportunity to realize a number of market opportunities in the coming year," McCarrey stated. "I am very pleased to join BioStem to champion the company’s team as it capitalizes on these opportunities.”
BioStem Technologies is focused on harnessing the natural properties of perinatal tissue in developing, manufacturing, and commercializing allografts for regenerative therapies. The company manufactures products leveraging its proprietary BioREtain processing method. BioREtain has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (AATB). These systems and procedures are established per current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). Its portfolio of brands includes AmnioWrap2, VENDAJE, VENDAJE AC, and VENDAJE OPTIC. Each BioStem Technologies placental allograft is processed at the company's U.S. Food and Drug Administration-registered and AATB-accredited site in Pompano Beach, Fla.